latest news stock values companies glp-1 obesity cardiometabolic Analogues Market Size to Hit USD 1,062.90 Billion by 2035 BREAKING: Eli Lilly's $1 trillion

If Medicare Part D already covers your GLP-1 for another FDA-approved usesuch as diabetes, cardiovascular disease, MASH, or obstructive sleep apneayoull continue receiving that medication through your Part D plan rather than the Bridge Program

JPML to centralize the litigation to reduce duplicative discovery into common issues that will arise in all claims, avoid conflicting pretrial rulings and to serve the convenience of certain witnesses and parties who will be required to testify in each of the lawsuits

PlexusDx recommends ongoing monitoring of nutrient status, particularly after the first 36 months of therapy, to identify any supplementation needs

Originally, they considered that the risk of cardiovascular disease associated with obesity resulted in higher costs than covering these medications for weight loss